Outsourcing-pharma2d
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Denmark boosts Arctic defence spending by $2.1 billion, responding to US pressure
Denmark said on Monday it would spend 14.6 billion Danish crowns ($2.05 billion) boosting its military presence in the Arctic ...
Denmark boosts Arctic defense spending by $2 billion after Trump’s Greenland interest
Denmark said on Monday it would spend 14.6 billion Danish kroner ($2.05 billion) boosting its military capabilities in the ...
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
MT Newswires on MSN6d
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes ...
ENDPOINTS NEWS6d
No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
STAT6d
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...